Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS).

Wen MT, Luo D, Li JC, Lu BW, Ling PX, Liu F, Li G

Expert opinion on drug safety18 Jul 2024Cited by 2 (Europe PMC)

PMID39016171DOI10.1080/14740338.2024.2382228PepBankPUB-39016171

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

01HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong arthralgia safety signal.
In plain wordsAbaloparatide was linked to a strong joint pain reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseArthralgia reporting signal
Study
n = 422,377
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617107
02HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong limb pain safety signal.
In plain wordsAbaloparatide was linked to a strong limb pain reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLimb pain reporting signal
Study
n = 422,377
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617108
03HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong back pain safety signal.
In plain wordsAbaloparatide was linked to a strong back pain reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBack pain reporting signal
Study
n = 422,377
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617109
04HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong muscle spasm safety signal.
In plain wordsAbaloparatide was linked to a strong muscle spasm reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseMuscle spasms reporting signal
Study
n = 422,377
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617110
05HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong bone pain safety signal.
In plain wordsAbaloparatide was linked to a strong bone pain reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone pain reporting signal
Study
n = 422,377
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617111
06HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong muscle pain safety signal.
In plain wordsAbaloparatide was linked to a strong muscle pain reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseMuscle pain reporting signal
Study
n = 422,377
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617112
07HumanObservational studySafety outcome
In FAERS reports, abaloparatide showed a strong muscle weakness safety signal.
In plain wordsAbaloparatide was linked to a strong muscle weakness reporting signal.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseMuscle weakness reporting signal
Study
n = 422,377
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617113
08HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong arthralgia safety signal.
In plain wordsTeriparatide was linked to a strong joint pain reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseArthralgia reporting signal
Study
n = 366,747
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617114
09HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong limb pain safety signal.
In plain wordsTeriparatide was linked to a strong limb pain reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLimb pain reporting signal
Study
n = 366,747
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617115
10HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong back pain safety signal.
In plain wordsTeriparatide was linked to a strong back pain reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBack pain reporting signal
Study
n = 366,747
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617116
11HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong muscle spasm safety signal.
In plain wordsTeriparatide was linked to a strong muscle spasm reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMuscle spasms reporting signal
Study
n = 366,747
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617117
12HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong bone pain safety signal.
In plain wordsTeriparatide was linked to a strong bone pain reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone pain reporting signal
Study
n = 366,747
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617118
13HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong muscle pain safety signal.
In plain wordsTeriparatide was linked to a strong muscle pain reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMuscle pain reporting signal
Study
n = 366,747
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617119
14HumanObservational studySafety outcome
In FAERS reports, teriparatide showed a strong muscle weakness safety signal.
In plain wordsTeriparatide was linked to a strong muscle weakness reporting signal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMuscle weakness reporting signal
Study
n = 366,747
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Both drugs exhibited strong signals for arthralgia, limb pain, back pain, muscle spasms, bone pain, muscle pain, and muscle weakness.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617120
15HumanObservational studySafety outcome
In FAERS reports, abaloparatide was linked to more nervous system adverse events than teriparatide.
In plain wordsAbaloparatide was linked to more nervous system adverse event reports than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseNervous system adverse event frequency
Study
n: not reported in source
Comparator
Teriparatide
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617101
16HumanObservational studySafety outcome
In FAERS reports, abaloparatide was linked to more cardiovascular adverse events than teriparatide.
In plain wordsAbaloparatide was linked to more cardiovascular adverse event reports than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCardiovascular adverse event frequency
Study
n: not reported in source
Comparator
Teriparatide
Outcome group
Adverse events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617102
17HumanObservational studySafety outcome
In FAERS reports, abaloparatide was linked to more gastrointestinal adverse events than teriparatide.
In plain wordsAbaloparatide was linked to more digestive adverse event reports than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseGastrointestinal adverse event frequency
Study
n: not reported in source
Comparator
Teriparatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617103
18HumanObservational studySafety outcome
In FAERS reports, teriparatide was linked to fewer nervous system adverse events than abaloparatide.
In plain wordsTeriparatide was linked to fewer nervous system adverse event reports than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNervous system adverse event frequency
Study
n: not reported in source
Comparator
Abaloparatide
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617104
19HumanObservational studySafety outcome
In FAERS reports, teriparatide was linked to fewer cardiovascular adverse events than abaloparatide.
In plain wordsTeriparatide was linked to fewer cardiovascular adverse event reports than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCardiovascular adverse event frequency
Study
n: not reported in source
Comparator
Abaloparatide
Outcome group
Adverse events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617105
20HumanObservational studySafety outcome
In FAERS reports, teriparatide was linked to fewer gastrointestinal adverse events than abaloparatide.
In plain wordsTeriparatide was linked to fewer digestive adverse event reports than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseGastrointestinal adverse event frequency
Study
n: not reported in source
Comparator
Abaloparatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Comparative analysis revealed a higher frequency of AEs related to the nervous, cardiovascular, and gastrointestinal systems for ABL compared to TP.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective, observational disproportionality analysis was conducted utilizing FAERS data from Q1 2004 to Q3 2023, where TP or ABL was identified as the primary suspect drug.
Report a problemFND-3901617106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS).

Summary

Results from this study20

Version history

Subjects

Publication types

MeSH terms

Keywords